Other inhibitors such as cysteamine, DNTB, adenanthin, and E64FC26 have shown promise in targeting specific PDI family members or pathways, with some entering preclinical testing for cancer or inflammatory disease [189]. This evidence concerns the gene P4HB and cancer.